Видео ютуба по тегу Oral Serd

The landscape of oral SERDs and their potential in ER+ breast cancer
The landscape of oral SERDs and their potential in ER+ breast cancer
Dialing Up Precision in HR+, HER2 MBC With New Therapies
Dialing Up Precision in HR+, HER2 MBC With New Therapies
New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer
New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer
Advanced HR-Positive Breast Cancer: Oral SERDs in Focus
Advanced HR-Positive Breast Cancer: Oral SERDs in Focus
Oral SERDs Explained: A New Option for Breast Cancer Patients
Oral SERDs Explained: A New Option for Breast Cancer Patients
SABCS 2024: Molecular Tumor Board
SABCS 2024: Molecular Tumor Board
lidERA trial: giredestrant improves invasive disease-free survival in ER+/HER2- early breast cancer
lidERA trial: giredestrant improves invasive disease-free survival in ER+/HER2- early breast cancer
Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2
Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2
Episode 1: Oral SERDs in ER+ breast cancer: efficacy, safety and treatment landscape
Episode 1: Oral SERDs in ER+ breast cancer: efficacy, safety and treatment landscape
Women’s Health Update – November 26, 2025: IBD Pregnancy Guidance, Oral SERD Win and More
Women’s Health Update – November 26, 2025: IBD Pregnancy Guidance, Oral SERD Win and More
Role of Oral SERDs in the Care of Patients with ER-Positive Metastatic Breast Cancer
Role of Oral SERDs in the Care of Patients with ER-Positive Metastatic Breast Cancer
SABCS 2021: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s...
SABCS 2021: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s...
SABCS 2023: State of the Art - Targeting Mutant ER
SABCS 2023: State of the Art - Targeting Mutant ER
How Are Oral SERDs Changing the Management of Advanced HR-Positive Breast Cancer?
How Are Oral SERDs Changing the Management of Advanced HR-Positive Breast Cancer?
AMEERA-3: SERD for ER+ HER2- breast cancer
AMEERA-3: SERD for ER+ HER2- breast cancer
SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC
SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC
Overview of Clinical Data of SERDs & Their Place in Treatment Landscape
Overview of Clinical Data of SERDs & Their Place in Treatment Landscape
The emerging role of SERD's in HR+ breast cancer
The emerging role of SERD's in HR+ breast cancer
Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer — Issue 7
Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer — Issue 7
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer
Visual Exploration of the Evolving Role of Novel Oral SERDs and More in ER+, HER2- MBC
Visual Exploration of the Evolving Role of Novel Oral SERDs and More in ER+, HER2- MBC
Episode 2: Oral SERDs in ER+ breast cancer: treatment selection and beyond
Episode 2: Oral SERDs in ER+ breast cancer: treatment selection and beyond
Oral SERDS: New endocrine therapy options in ER+ metastatic breast cancer - a patient case video
Oral SERDS: New endocrine therapy options in ER+ metastatic breast cancer - a patient case video
The Use of Oral Selective Estrogen Receptor Degraders for HR-Positive Metastatic Breast Cancer
The Use of Oral Selective Estrogen Receptor Degraders for HR-Positive Metastatic Breast Cancer